Compare Novo Nordisk A/S (NVO) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tidewater Inc — how do they compare? Novo Nordisk A/S trades at $46.52 (market cap $207.85B), while Tidewater Inc trades at $91.74 (market cap $4.54B). The key difference: Novo Nordisk A/S is far larger — about 45.8× Tidewater Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| NVO | TDW | |
|---|---|---|
Market Cap | $207.85B | $4.54B |
Sector | Health | Utilities |
52-Week High | $63.98 | $91.20 |
52-Week Low | $35.29 | $47.29 |
Enterprise Value | $222.55B | $4.58B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Tidewater (TDW) trades at $91.61, up 2.21% with strong technical momentum and bullish moving average signals. The company reported Q2 2026 earnings of $0.43 per share, beating estimates, with revenue of $342.3 million. Despite recent earnings misses, operational cash flow remains robust at $379 million for 2025, though 2026 projections show declining revenue and margins. Analyst sentiment is mixed with 26.9% buy ratings amid elevated RSI levels suggesting potential overbought conditions.
The stock faces headwinds from declining profitability trends and earnings volatility, but strong institutional ownership and positive technical indicators support near-term upside. Key risks include execution challenges and macroeconomic pressures on the offshore services sector. Investors should weigh solid cash generation against margin compression for balanced positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
